GENEVA, Switzerland, July 16 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that the Japanese Ministry of Health, Labor and Welfare has granted approval to ...

Merck Serono announced that the FDA has approved EMD Serono‘s GONAL-f RFF Redi-ject (recombinant follitropin alfa) injection, a disposable prefilled drug injector pen indicated for the subcutaneous ...

Geneva, Switzerland and Rockland, MA, May 27, 2004 -- Serono, Inc., the US affiliate of Serono (virt-x: SEO and NYSE: SRA), announced today that the United States Food and Drug Administration (FDA) ...

EMD Serono announced that Gonal-f RFF Redi-ject (recombinant follitropin alfa), a disposable prefilled drug injector pen intended for subcutaneous injection of a liquid formulation of Gonal-f RFF ...

Gonal-f ® RFF Redi-ject™ (follitropin alfa injection) is indicated for: Induction of ovulation and pregnancy in oligo-anovulatory women in whom the cause of infertility is functional and not due to ...

GENEVA, July 4, 2011 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that the European Commission (EC) has granted an approval for three pre-filled, ...

EMD Serono’s complete fertility medication portfolio, including Gonal‑f®, the most‑prescribed follicle‑stimulating hormone in the U.S., is now accessible via TrumpRx.gov and ...

DARMSTADT, Germany — The Food and Drug Administration has approved a pre-filled injector pen made by EMD Serono for infertile women, the company said Friday. The drug maker — the U.S. subsidiary of ...